3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Leukemia, Promyelocytic, Acute
4
Leukemia
3
Neuroblastoma
2
Multiple Myeloma
2
Leukemia, Myeloid, Acute
2
Wilms Tumor
1
Testicular Neoplasms
1
Teratoma
1
Skin Neoplasms
1
Sarcoma
1
Retinoblastoma
1
Recurrence
1
Ovarian Neoplasms
1
Ovarian Germ Cell Cancer
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Medulloblastoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Kidney Neoplasms
1
Hepatoblastoma
1
Endometrial Neoplasms
1
Desmoplastic Small Round Cell Tumor
1
Childhood Acute Promyelocytic Leukemia With PML-RARA
1
Central Nervous System Neoplasms
1
Carcinoma, Small Cell
1
Interventions
aldesleukin
15
Cyclophosphamide
15
fludarabine phosphate
12
fludarabine
11
Interleukin-2
10
Nivolumab
6
Ipilimumab
6
Temozolomide
5
pembrolizumab
3
Fluorouracil
3
trametinib
2
sonidegib
2
dabrafenib
2
binimetinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Tacrolimus
2
Sodium Chloride
2
Sirolimus
2
Radiotherapy
2
Radiation
2
Peptides
2
HhAntag691
2
Gefitinib
2
Dacarbazine
2
Cyclosporine
2
Cetuximab
2
Capecitabine
2
veliparib
1
varlilumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Skin Neoplasms
×
Arsenic Trioxide
×
Clear all
NCT01791894
2018-06-08
ATO
Stanford University
Phase 1/2
Completed
5 enrolled
9 charts